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ABSTRACT
Head and neck squamous cell carcinoma (HNSCC) is a particularly aggressive 
cancer with poor prognosis, largely due to lymph node metastasis and local 
recurrence. Emerging evidence suggests that epithelial-to-mesenchymal transition 
(EMT) is important for cancer metastasis, and correlated with increased cancer stem 
cells (CSCs) characteristics. However, the mechanisms underlying metastasis to 
lymph nodes in HNSCC is poorly defined. In this study, we show that E-cadherin 
repression correlates with cancer metastasis and poor prognosis in HNSCC. We found 
that G9a, a histone methyltransferase, interacts with Snail and mediates Snail-induced 
transcriptional repression of E-cadherin and EMT, through methylation of histone H3 
lysine-9 (H3K9). Moreover, G9a is required for both lymph node-related metastasis 
and TGF-β-induced EMT in HNSCC cells since knockdown of G9a reversed EMT, 
inhibited cell migration and tumorsphere formation, and suppressed the expression 
of CSC markers. Our study demonstrates that the G9a protein is essential for the 
induction of EMT and CSC-like properties in HNSCC. Thus, targeting the G9a-Snail axis 
may represent a novel strategy for treatment of metastatic HNSCC.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) 
is the sixth most common cancer in the world with an 
annual incidence of over 560,000 cases [1]. Despite a 
variety of advances in combined-modality treatments, 
survival for HNSCC patients has been remained poor 
over the past two decades, due in large part to uncontrolled 
metastasis and local recurrence. HNSCC metastasis is 
primarily to lymph nodes [2] and the most important 
adverse prognostic factor in HNSCC is metastasis to 
cervical lymph nodes [3–5]. Certain genetic expression 
profiles in the primary tumor might predict the incidence 
of lymph node metastasis [6]. This finding suggests that 
genetic factors might direct early metastatic cells to 
lymph nodes in head and neck. Thus, identification of the 
genetic and molecular factors involved in this metastatic 
process are crucial to advance our understanding of 
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HNSCC metastasis, and for insight into the development 
of therapeutic strategies to improve survival in HNSCC 
patients.
Emerging evidence suggests that epithelial-
mesenchymal transition (EMT) plays an important role 
in cancer metastasis. EMT is an essential phenotypic 
conversion during embryonic development, tissue 
remodeling, wound healing, and cancer metastasis [7–9]. 
During EMT, cells loose epithelial characteristics such as 
cell polarity and cell-cell contact, and gain mesenchymal 
properties such as motility [10]. EMT is a dynamic and 
reversible process, and is provoked by signals from the 
microenvironment [11–13] such as TGF-β, Wnt, and TNFα 
[14, 15]. TGF-β, a pluripotent factor, [16] is a significant 
element for EMT induction in epithelial cells during 
embryonic development and cancer progression [7]. This 
factor stimulates cancer cells to become both motile and 
invasive, thereby leaving the primary tumor site, and 
disseminate to distant sites of the body. Importantly, when 
metastatic cancer cells migrate, the signals encountered 
are different from those obtained in the primary tumor, 
and cells can revert to an epithelial state by mesenchymal-
epithelial transition (MET) [8, 17, 18].
A hallmarker of EMT is lost of E-cadherin 
expression [8]. In fact, decreased or complete loss of 
E-cadherin expression is associated with metastasis to 
lymph nodes and poor prognosis in HNSCC [19]. Promoter 
methylation, mediated by E-box-binding transcription 
repressors such as Snail, Twist and Slug, likely impacts 
on the repression of E-cadherin during EMT [20]. In 
fact, upregulated Snail correlates with local recurrence in 
HNSCC [21]. Snail can induce epigenetic modifications, 
such as DNA methylation and histone modifications, and 
these processes play an important role in the regulation of 
gene expression for proteins like E-cadherin during EMT 
[22]. Histone methylation of the Lys9 and Lys27 residues 
of histone H3 (H3K9me2/3 and H3K27me3) represses 
gene expression; in contrast, histone acetylation of H3K4 
(H3K4Ac) and H3K9 (H3K9Ac) is associated with gene 
activation [23].
Recently, G9a, a Snail-interacting protein, emerged 
as an important mediator of Snail-induced EMT. G9a, 
also called EHMT2 or KMT1C, is a major euchromatic 
methyltransferase, which mediates gene silencing in 
euchromatin by mono- and di-methylation of on histone 
3 lysine 9 (H3K9) [24]. G9a can cooperate with other 
transcription factors to regulate gene expression [25], 
and is reportedly involved with important cancer-
sustaining cellular activities such as cell proliferation, 
autophagy, EMT, metabolic changes, specific responses 
to hypoxia and cancer stemness [26–30]. Recent studies 
show that G9a is highly expressed in many types of 
malignant tissue, including HNSCC, when compared 
to paired normal tissue [31, 32]. However, it is still 
unknown whether G9a plays a role in HNSCC metastasis 
to lymph nodes.
Since cancer stem cells (CSCs) are capable of 
self-renew and proliferation, they are thought to initiate 
tumorigenesis, as well as tumor recurrence after treatment. 
In addition, CSCs are likely responsible for therapeutic 
resistance and metastasis in HNSCC. CD44, a CSC marker 
in HNSCC, plays a role in tumor metastasis [33]. CD44 
is a cell-surface glycoprotein that functions as a receptor 
for hyaluronic acid and is involved in cell adhesion and 
migration [34]. In HNSCC, a subpopulation of CD44+ 
CSCs displays a phenotypic switch, and become either 
proliferative or migratory [35]. Recent studies suggest that 
EMT in cancer cells is a process crucial for the acquisition 
of “stemness”, the ability to become a CSC [36]. However, 
the molecular mechanisms underlying stemness and 
metastasis in HNSCC are obscure.
In this study, we investigated the role of G9a in 
the induction of EMT and CSC-like characteristics in 
HNSCC. We found that G9a, through interaction with 
Snail, is required for both metastasis to lymph nodes and 
TGF-β induced EMT in HNSCC. Our study provides a 
plausible mechanism for metastasis to lymph nodes and 
EMT in HNSCC.
RESULTS
Lost of E-cadherin is associated with metastasis 
and poor clinical outcome in HNSCC
As loss of E-cadherin expression is a hallmarker of 
EMT, we first screened the expression level of E-cadherin 
in a panel of HNSCC cell lines. Immunoblot analysis 
showed a significant suppression of E-cadherin in HN12 
as compared to other cell lines such as HN4 (Figure 1A). 
It was reported that HN12 and HN4 cells were derived 
from the same patient, but HN12 was a nodal metastatic 
subclone from HN4 cells [37]. This information suggests 
that loss of E-cadherin expression may be a crucial step 
for conversion from a non-metastatic (HN4) to metastatic 
(HN12) state in this HNSCC patient. To investigate the 
potential relationship between EMT and metastasis, we 
examined E-cadherin expression in HNSCC patients using 
a dataset from Oncomine, which includes 34 HNSCC 
and 4 normal uvula samples analyzed by Affymetrix 
U95A microarrays [38]. The analysis demonstrates that 
E-cadherin expression was higher in patients without 
metastasis whereas it was significantly lower in patients 
with metastasis (Figure 1B). Although the trend is 
consistent with our assumption, that repression of 
E-cadherin is associated with poor prognosis in HNSCC, 
the difference by Kaplan–Meier survival analysis was 
not statistically significant, possibly resulting from the 
limited number of cases available (Figure S1A and 
S1B). However, when the statistical analysis combined 
the metastatic status and E-cadherin expression level, the 
5 year survival of patients with low E-cadherin expression 
and metastasis (M) was significantly shorter than survival 
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with high E-cadherin and no metastasis (NM) (Figure 1C 
and 1D). Taken together, these results suggest that loss of 
E-cadherin expression correlates with HNSCC metastasis, 
a negative prognostic indicator in patients with HNSCC.
EMT plays a key role in metastasis to lymph 
nodes of HNSCC
To investigate the molecular mechanisms involved 
in HNSCC metastasis to lymph nodes, we selected HN4 
and HN12 as a paired cell line for further characterization, 
since HN12 and HN4 cells were derived from the same 
patient, with HN12 a nodal metastatic subclone from the 
HN4 primary tumor [37]. HN4 cells exhibit the typical 
polygonal morphology for epithelial cells (Figure 2A). 
Immunofluorescent analysis showed high expression 
levels of the epithelial marker E-cadherin and low levels 
of mesenchymal markers N-cadherin and vimentin in 
HN4 cells (Figure 2A). In contrast, HN12 cells were 
scattered throughout the plate surface, displayed a 
fibroblast-like morphology, and expressed low levels of 
E-cadherin and high levels of the N-cadherin and vimentin 
(Figure 2A and 2B). Immunoblot analysis confirmed the 
molecular features of these two cell lines (Figure 2B). 
Next, we examined the migratory capabilities of HN4 
and HN12 cells, an EMT-associated biological activity, 
using a transwell migration assay. HN12 cells exhibited 
a significantly higher motility than did the HN4 cells 
(Figure 2C and 2D). Taken together, these results 
indicate that HN12 cells gain EMT-related molecular and 
functional phenotypic changes relative to their companion 
HN4 cells. Thus, EMT may play a key role in metastasis 
to lymph nodes in HNSCC.
G9a interacts with snail and binds to the 
promoter of E-cadherin as a complex
G9a is a critical component of Snail-induced 
repression of E-cadherin in human breast cancer [27], but 
its involvement in lymph node metastasis in HNSCC is 
Figure 1: E-cadherin repression is associated with metastasis and poor clinical outcome in head and neck squamous 
cell carcinoma (HNSCC). (A) Western blot of E-cadherin, G9a and Snail using different HNSCC cell lines. “M” indicates the metastatic 
subtype of HN12 cells derived from a nodal metastasis. (B) E-cadherin mRNA levels and metastatic status of patients from an Oncomine 
dataset (Mean ± SD, p < 0.05). “NM” means “none-metastasic”; “M” means “metastasic”. (C–D) Kaplan-Meier survival curves demonstrate 
the 5-year survival analysis of combined metastasis status and E-cadherin expression level in HNSCC patients from an Oncomine dataset.
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unknown. To identify a relationship between E-cadherin 
and G9a, we analyzed the expression of E-cadherin 
and G9a from Oncomine data sets, which contain 34 
HNSCC tumor samples (Figure S1C). We did not find 
any correlation in the expression of E-cadherin with 
G9a at the mRNA level in this gene expression data set. 
Similarly, examination of E-cadherin and G9a protein 
levels in a panel of HNSCC cell lines did not reveal any 
correlation in protein expression (Figure 1A). To explore 
the potential involvement of G9a, we examined the 
interaction of G9a with Snail by co-immunoprecipitation 
(Co-IP) following transient transfection of HEK293T 
cells with Flag-tagged G9a and GFP-tagged Snail. The 
analysis confirmed that G9a and Snail interact to form 
a complex, since immunoprecipitation of either G9a or 
Snail revealed the other molecule (Figure 3A and 3B). 
Importantly, only the metastatic HNSCC cell line, HN12, 
showed a physical interaction between endogenous Snail 
and G9a (Figure 3C–3D); this interaction was not detected 
in the non-metastatic HNSCC cell line HN4 (Figure 3E). 
These findings suggest that the interaction between G9a 
and Snail may be crucial for the promotion of metastatic 
features in HN12 cells.
To determine if the G9a-Snail complex influences 
E-cadherin repression, we performed chromatin 
immunoprecipitation (ChIP) analysis on the E-cadherin 
promoter of HN4 and HN12 cells. We found dramatically 
higher levels of H3K9me2, an indicator of gene silencing, 
at the E-cadherin promoter of HN12 cells when compared 
to levels found in HN4 cells (Figure 3F). In contrast, H3K9 
acetylation, an indicator of gene expression, was much 
lower at the E-cadherin promoter in HN12 cells than that 
Figure 2: Lymph node metastatic HNSCC cells exhibit EMT characters. (A) Morphology and staining for E-cadherin, 
N-cadherin and vimentin in HN-4 and HN12 cells. Scale bar = 200 μm. (B) Western blot analysis of E-cadherin, N-cadherin, Claudin-1, 
vimentin and Snail protein levels in HN4 and HN12 cell lines. (C) The transwell migration assay identified the migration capability of HN4 
and HN12 cells with representative images shown. Scale bar = 200 μm. (D) Graph demonstrates the mean ± SD for the percent of migrated 
cells from 3 separate experiments.
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in HN4 cells (Figure 3F). The elevated levels of H3K9me2 
at the E-cadherin promoter are likely due to formation of 
a Snail–G9a complex because the occupancy of Snail and 
G9a at the E-cadherin promoter was significantly higher 
in HN12 cells than in HN4 cells (Figure 3F). Thus, in 
metastatic HN12 cells, G9a forms a complex with Snail 
and binds to the E-cadherin promoter, which results in 
H3K9me2 and eventually DNA methylation; these events 
increase the potential for EMT and metastasis to lymph 
nodes in this HNSCC cell line.
G9a-mediated H3K9 methylation is required for 
TGF-β-induced EMT in HNSCC
It appears that HN12 cells are ‘locked’ in the 
mesenchymal state since the E-cadherin promoter is 
methylated in these cells; this situation makes it difficult to 
study the initial and dynamic events of EMT in HNSCC. 
To overcome this technical issue, we investigated the 
mechanisms underlying histone modification and DNA 
methylation during TGF-β-induced EMT in HN4 cells. 
We found that, TGF-β treatment (5 ng/ml) induced EMT 
in HN4 cell as characterized by acquisition of fibroblastic 
mesenchymal morphology (Figure 4A), downregulation 
of the epithelial marker E-cadherin, and upregulation 
of mesenchymal markers N-cadherin and vimentin 
(Figure 4A and 4D). The transwell migration assay showed 
that TGF-β treatment significantly increased the number 
of migrating cells, suggesting that TGF-β increased the 
motility of HN4 cells (Figure 4B and 4C). Moreover, 
ChIP analysis showed that TGF-β treatment significantly 
increased H3K9me2, and decreased H3K9 acetylation 
at the E-cadherin promoter in HN4 cells (Figure 4E). 
Taken together, the results suggest that H3K9me2 is 
involved in TGF-β-induced EMT in HNSCC. Because the 
methyltransferase activity of G9a is specific, the elevated 
level of H3K9me2 on the E-cadherin promoter implies 
that G9a might be involved in regulation of E-cadherin 
expression. To determine if the G9a-Snail complex in the 
E-cadherin promoter is essential for E-cadherin repression 
in HNSCC, we examined the effects of an inhibitor of 
G9a, BIX01294, on the H3K9me2 methyltransferase 
activity in the TGF-β-induced EMT model. BIX01294 
treatment reversed the EMT phenotype induced by TGF-β 
Figure 3: G9a interacts with Snail and binds to the E-cadherin promoter. (A–B) 293T cells were transiently transfected 
with Flag-tagged G9a GFP-tagged Snail plasmids. Western blot analysis of cell extracts immunoprecipitated (IP) with either Flag or GFP 
antibodies, and their associated G9a, and Snail proteins. (C, D, E) Endogenous Snail and G9a were immunoprecipitated from HN12 and 
HN4 cells, and examined by Western blot. (F) ChIP analysis demonstrates the association of G9a, Snail, and the level of H3K9me2 and 
H3K9 acetylation at the E-cadherin promoter in HN4 and HN12 cell lines.
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treatment: the fibroblastic mesenchymal morphology 
reverted to the polygonal epithelial morphology 
(Figure 5A). Moreover, BIX01294 treatment upregulated 
E-cadherin expression (Figure 5B) and reduced the wound 
healing activity in the TGF-β-induced EMT model (Figure 
5C–5D). Consistently, ChIP analysis showed that BIX 
treatment significantly decreased the level of H3K9me2 
and increased the level of H3K9Ac on the E-cadherin 
promoter (Figure 5E), which accounts for the upregulated 
E-cadherin in BIX-treated cells. Thus, G9a is essential for 
the formation of H3K9me2 on the E-cadherin promoter, 
which mediates TGF-β-induced EMT in HNSCC cells.
To confirm this observation, we established stable 
shRNA-G9a transfectants of HN12 cells with knockdown 
of G9a expression. The knockdown efficiency of 
endogenous G9a by shRNA was about 80% (Figure 6B). 
Knockdown of G9a restored E-cadherin expression and 
dramatically downregulated N-cadherin and vimentin in 
HN12 cells (Figure 6A and 6B). In addition, knockdown 
of G9a greatly inhibited the motility and migration of 
HN12 cells (Figure 6C and 6D). Taken together, these 
results strongly support the assertion that G9a is essential 
for repression of E-cadherin, with subsequent EMT and 
metastasis to lymph nodes in HNSCC.
Induction of CSC characters is associated with 
EMT in HNSCC
Recent studies suggest that EMT is involved in 
acquisition of CSC properties, such as an increased ability 
to form tumorspheres, and expression of stem cell-like 
markers [36]. To determine whether the EMT status of 
HNSCC enhances CSC characteristics, especially in EMT-
related metastasis to lymph nodes, we performed a series 
of experiments with the HN4 and HN12 cell lines. We 
found tumorsphere formation significantly increased in 
HN12 cells when compared with formation in HN4 cells 
(Figure 7A and 7B). Next, we examined the CSC marker 
CD44 in HNSCC cells by Western blot analysis [33]; 
CD44 expression increased in HN12 cells when compared 
Figure 4: H3K9 methylation at the E-cadherin promoter is associated with TGF-β–induced EMT in HNSCC. (A) HN4 
cells were treated with TGF-β1 (5 ng/ml) for 3, 6, 9, 12 and 15 days, respectively; morphologic changes associated with EMT at 12 days 
are shown in the phase contrast images. Immunofluorescence (IF) staining for E-cadherin, N-cadherin and vimentin is presented with 
nuclei stained with DAPI (blue). Scale bar = 200 μm. (B) Migration of HN4 cells exposed to TGF-β (5 ng/ml) for 6 days before assay 
with representative images shown. Scale bar = 200 μm. (C) Graph demonstrates the mean ± SD percent of migrated cells from 3 separate 
experiments. (D) Western blot analysis of E-cadherin, N-cadherin and Snail in HN4 cells treated with TGF-β (5 ng/ml) for the indicated 
time periods. (E) ChIP analysis of H3K9me2 and H3K9Ac at the E-cadherin promoter of HN4 cells treated with TGF-β (5 ng/ml).
Oncotarget6893www.impactjournals.com/oncotarget
with expression levels in HN4 cells (Figure 7C and 7D). 
Consistently, FACS analyses also showed CD44 positive 
cells significantly increased in HN12 cells when compared 
with levels in HN4 cells (Figure S2A–S2B). Moreover, 
colony formation in soft agar was significantly greater 
in HN12 cells than in HN4 cells (Figure S2C and S2D). 
Consistent with these observations, TGF-β treatment of 
HN4 cells increased the tumorsphere-formation and CD44 
expression (Figure 7E and 7G), suggesting that TGF-β-
induced EMT is associated with increased CSC characters 
in HNSCC. Taken together, these observations suggest that 
induction of EMT in HNSCC generates CSC-like cells.
G9a is essential for EMT-induced CSC 
characters in HNSCC
Since G9a is essential for TGF-β-induced EMT, and 
EMT induces CSC-like characteristics, we asked whether 
G9a is essential for induction of CSC-like characteristics 
in HNSCC. TGF-β treatment induced expression of 
the CD44 marker in HN4 cells (Figure 8A). However, 
addition of a G9a inhibitor BIX01294 suppressed CD44 
expression, suggesting that a functional G9a is required for 
TGF-β-induced CD44 expression in these cells. 
Consistently, BIX01294 also suppressed TGF-β-induced 
tumorsphere-formation (Figure 8B and 8C). These results 
suggest that a functional G9a is required for TGF-β-induced 
CSC-like characters. To determine if G9a is essential for 
maintenance of CSC-like characteristics, we examined and 
compared the biochemical and biological characteristics 
of stable shRNA-G9a transfectants (knockdown of 
G9a expression) with HN12 cells. Knockdown of G9a 
expression significantly suppressed CD44 expression when 
levels were compared to control HN12 cells, suggesting 
that G9a is required for CD44 expression (Figure 8D, 
8E and Figure S3). Moreover, knockdown of G9a also 
suppressed tumorsphere formation in the transfected cells 
compared with formation in control HN12 cells (Figure 8F 
and 8G). Taken together, these observations demonstrate 
that G9a is essential for induction and maintenance of 
EMT-related CSC-like characteristics in HNSCC.
DISCUSSION
In this study, we show that repressed E-cadherin 
expression correlates with cancer metastasis and poor 
Figure 5: G9a inhibitor BIX01294 reverses TGF-β–induced EMT in HNSCC cells. (A) Morphologic changes of HN4 cells 
treated with or without BIX01294 (BIX: 2.5 μM) followed by treatment with TGF-β1 (5 ng/ml) for 5 days. (B) Western blot analysis of 
E-cadherin protein levels of BIX-treated HN4 cells with and without additional TGFβ treatment. (C) Wound healing and migratory analysis 
of HN4 cells treated with or without BIX01294 followed by TGF-β1 (5 ng/ml) treatment. Scale bar = 200 μm. (D) Graph demonstrates the 
migratory ability of HN4 cells (mean ± SD) treated with or without BIX01294 followed by TGF-β1 (5 ng/ml) treatment from 3 separate 
experiments. (E) ChIP analysis of H3K9me2 and H3K9 acetylation at the E-cadherin promoter of BIX-treated HN4 cells with and without 
additional TGF-β treatment.
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prognosis in HNSCC. We found that G9a is essential 
for Snail-induced repression of E-cadherin and EMT in 
HNSCC cells. Furthermore, we demonstrated that G9a is 
required for induction of CSC-like characters in HNSCCs. 
Thus, the Snail-G9a axis is a vital component of metastatic 
HNSCC, and provides a potential therapeutic target for 
this disease.
Metastasis, the major cause of cancer deaths, is 
a multistep process consisting of four distinct steps: 
invasion, intravasation, extravasation and metastatic 
colonization. The initiation of tumor cell migration is a 
prerequisite for the metastatic cascade. EMT, considered 
the most important step in initiating cancer metastasis, 
associates with decreased or complete loss of E-cadherin 
expression in HNSCC metastatic to lymph nodes [19]. 
These conclusions were obtained from various analyses 
including IHC [39, 40] and mRNA array (Figure 1). Many 
transcriptional repressors, such as Snail, Slug, Twist, 
ZEB1, ZEB2, have been implicated in the regulation of 
EMT for a variety of cancers, including breast cancer, 
colon cancer, liver and HNSCC [27, 41–44]. For example, 
Slug, Twist, Snail and ZEB1 are important in E-cadherin 
repression, and thus regulating EMT, especially in breast 
cancer. In this study, we have shown that the Snail-G9a 
axis plays a critical role in mediating EMT in HNSCC. 
Our observation is supported by Mendelsohn [45] who 
Figure 6: Knockdown of G9a expression inhibits cell migration in HNSCC. (A) Morphologic changes in stably transfected 
HN12 cells with knockdown of G9a and control HN12 cells by phase contrast microscopy. Immunofluorescence (IF) staining for E-cadherin, 
N-cadherin and vimentin is presented with nuclei stained with DAPI (blue). Scale bar = 200 μm. (B) Western blot analysis of E-cadherin, 
N-cadherin and vimentin in HN12 cells stably expressing control vector or G9a shRNA. (C) Migration of HN12 cells stably expressing 
control vector or G9a shRNA analyzed using the transwell migration assay. Scale bar = 200 μm. (D) Graph demonstrates the mean ± SD 
percent migrated cells in HN12 vector control and shG9a cells from 3 separate experiments.
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used IHC to demonstrated an upregulated Snail expression 
in HNSCC, along with a correlation between Snail levels 
and metastasis in this disease. However, other pathways 
may contribute to EMT in HNSCC. For example, Slug 
and Twist were upregulated in HNSCC metastatic sites, 
and both promote EMT-mediated metastasis. However, the 
molecular mechanisms regulating these proteins require 
further investigation.
Figure 7: Stem cell-like characters is involved in the EMT process in HNSCC. (A) Representative image of tumorsphere 
formation in HN4 and HN12 cells. Scale bar = 200 μm. (B) Measurement of tumorsphere formation (mean ± SD from 3 separate experiments) 
in HN12 and HN4 cells. (C) Western blot analysis of CD44 in HN4 and HN12 cells. (D) Images are immunofluorescent staining of CD44 in 
HN4 and HN12 cells. (E) Representative image of tumorsphere formation in HN4 cells with or without TGF-β treatment. (F) Measurement 
of tumorsphere formation (mean ± SD from 3 separate experiments) in HN4 cells with or without TGF-β treatment. (G) Western blot 
analysis of CD44 in HN4 cells with or without TGF-β treatment.
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The Snail-G9a complex is bound to the E-cadherin 
promoter in HN12 cells but not in HN4 cells. The 
expression level of G9a is similar in HN12 and HN4 cells, 
but Snail expression is high in HN12 cells, and barely 
detectable in HN4 cells. This observation strongly supports 
the hypothesis that Snail level is the key factor for EMT 
induction. However, both Snail-induced and TGF-β-induced 
repression of E-cadherin require G9a since knockdown 
of G9a by shRNA or suppression of G9a activity by G9a 
inhibitor BIX reverse EMT markers and inhibit HNSCC 
cell migration. Thus, G9a is a major component mediating 
Snail-induced effects, at least in the HNSCC cells tested.
G9a is a key methyltransferase responsible for 
mono- and di-methylation of lysine 9 on histone 3 
(H3K9) of euchromatin and facultative heterochromatin 
[24]. Recent studies demonstrate that G9a is vital for 
Snail-mediated EMT in human breast cancer [27]. Our 
study extends these findings, confirms the importance 
of G9a epigenetic modification on the E-cadherin 
promoter in HNSCC, and reinforces the view that EMT 
is an epigenetic event. In addition to facilitating Snail 
functions, G9a also interacts with other transcription 
factors, including Sharp-1, Gfi1, NF-κB, CDP, and REST. 
In a manner similar to the Snail-G9a complex, these 
Figure 8: Knockdown of G9a inhibit tumorsphere formation and suppress the expression of CD44. (A) Western blot 
analysis of CD44 expression in HN4 cells treated without or with BIX (2.5 μM) followed by treatment with TGF-β (5 ng/ml). (B) 
Representative image of tumorsphere formation in HN4 cells treated without or with BIX (2.5 μM) followed by treatment with TGF-β  
(5 ng/ml). (C) The tumorsphere formation was measured in HN4 cells treated without or with BIX (2.5 μM) followed by treatment with 
TGF-β (5 ng/ml). Mean ± SD from 3 separate experiments. (D) Western blot analysis of CD44 expression in HN12 cells stably expressing 
control vector or G9a shRNA. (E) Image of immunofluorescence staining for CD44 expression. (F) Image of tumorsphere formation in 
HN12 cells stably expressing control vector or G9a shRNA. Scale bar = 200 μm. (G) Graph demonstrates the mean ± SD for tumorsphere 
number in HN12 cells stably expressing control vector or G9a shRNA from 3 separate experiments.
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proteins complex with and are recruited to distinct target 
promoters [46–50]. For example, G9a interacts with 
Sharp-1 and enhances Sharp-1–dependent repression of 
MyoD in a methyltransferase activity-dependent manner 
[46]. While primarily thought to generate H3K9me2 for 
transcriptional repression, G9a plays a more complicated 
role in regulating the transcriptional activation of other 
genes. For example, G9a can be recruited to and activate 
the β globin locus in an NF-E2/p45-dependent manner 
[51]. Similarly, G9a can act as a co-activator together 
with GRIP1, CARM1 and p300 for nuclear receptors 
in a methyltransferase-independent manner [58]. For 
example, recruited G9a is bound to the glucocorticoid 
receptor (GR) binding site, and functions as a scaffold 
for the recruitment of p300 and CARM1 to activate 
gene expression. In addition, Runx2 recruits G9a to 
MMP-9, CSF-2, SDF-1 and CST7 promoters to 
activate their expression in a methyltransferase activity-
independent manner [52]. Together these studies 
demonstrate that G9a is a multifunctional regulator of 
gene expression that can function either as a repressor or 
as an activator. We found that on one hand, G9a interacts 
with Snail and plays a “repressor” role for E-cadherin 
expression, whereas knockdown of G9a blocked CD44 
expression, suggesting that G9a acts as an “activator” 
of CD44 expression. However, it is unclear whether the 
regulation of CD44 expression by G9a is direct, that is, 
regulated at the promoter, or indirect and through other 
mechanisms.
Recent and transformative studies show that EMT 
is capable of introducing stem-like properties in epithelial 
cells [36]. CSC is a subpopulation of cells with self-
renewing capacities, believed to confer resistance to 
chemo- and radio-therapy and is responsible for tumor 
maintenance and metastasis [53]. The CSCs hypothesis 
suggests that tumors can arise from stem or progenitor 
cells. Importantly, many studies show that EMT can 
confer tumor cells with stem cell-like characteristics 
[36, 54, 55]. Proposed mechanisms for the EMT-induced 
stem-like properties of cancer cells vary. For example, a 
report indicates that ZEB1 inhibits the expression of the 
miR-200 family, resulting in upregulation of polycomb 
protein Bmi1 and induction of stemness in pancreatic 
cancer [59]. In HNSCC, one study showed that the EMT 
inducer Twist1 directly activates Bmi1 transcription, and 
that Twist and Bmi1 act cooperatively to induce EMT 
and stemness [56]. In this study, we found CSC-related 
characteristics induced in both lymph node-related EMT 
(HN12 cells) and TGF-β-induced EMT (HN4 cells). These 
data suggest that there is a biological link between CSC 
and EMT in HNSCC. As expected, inhibition of G9a by 
the inhibitor BIX not only repressed CD44 expression in 
HN12 cells and TGF-β-induced EMT in HN4 cells, but 
also suppressed the tumorsphere-formation. Thus, G9a 
is critical for both induction of EMT and maintenance of 
stem cell-like properties.
Because EMT influences both CSC properties and 
metastatic activity, targeting the EMT/CSC phenotype 
becomes an attractive strategy for the treatment of 
metastasis and tumor reoccurrence. Thus, targeting Snail–
G9a axis may represent a novel approach for treating 
and/or preventing metastatic HNSCC. Many cancers 
show an upregulation of both Snail and G9a including 
HNSCC [31, 32, 57]. Because either knockdown of 
G9a expression or suppression by BIX01294 inhibits 
migration and tumorsphere formation, targeting Snail and 
G9a, or their interaction, may repress EMT and the stem 
cell-like properties in HNSCC. Further investigation in 
targeting the Snail-G9a axis with animal tumor models 
is desirable.
In summary, mediation of Snail-induced EMT 
and repression of E-cadherin in HNSCC cells requires a 
functional G9a protein. Moreover, a link exists between 
EMT and CSC in HNSCC. Thus, targeting the G9a-
Snail axis may represent an attractive strategy to target 
metastatic and tumor recurrence in HNSCC.
MATERIALS AND METHODS
Plasmids and antibodies
Preparation of the expression plasmid for human 
Snail was described previously [15]. Antibodies against 
actin and GAPDH were from Santa Cruz Biotechnology 
(Santa Cruz, CA). Antibodies for E-cadherin, N-cadherin, 
vimentin, CD44, Snail, and Claudin-1 were from Cell 
Signaling Technology Inc. (Beverley, MA,). G9a, 
H3K9me2, and H3k9Ac antibodies were from Abcam 
(Cambridge, MA).
Cell cultures
The head and neck squamous cell carcinoma -derived 
cell lines HN4, HN6, HN12, HN13, HN30 were kindly 
provided by the University of Maryland, School of Dentistry. 
HN4 cancer cells, derived from a primary squamous cell 
carcinoma of the tongue, have an epithelial phenotype 
and low invasive capacity. HN12 cancer cells exhibit a 
mesenchymal phenotype and have high invasive capacity; 
they were derived from a nodal metastasis in the patient 
from whom the HN-4 cells originated [37, 60]. The CAL27 
cell line was purchased from the American Type Culture 
Collection (ATCC; Manassas, VA). All cells were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM; GIBCO, 
CA) supplemented with 10% FBS, 1% glutamine, and 1% 
penicillin–streptomycin, and maintained in a humidified 
atmosphere of 5% CO2 at 37°C.
Establishment of HN12 cells with knockdown 
of G9a expression was accomplished by transfection 
with G9a shRNA (Sigma-Aldrich, St. Louis, MO), and 
stable clones selected with puromycin (500 ng/ml) for 
4 weeks.
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Immunostaining, immunoprecipitation, and 
immunoblotting
Experimental protocols for immunoprecipitation and 
immunoblotting follow those previously described [61]. 
For immunofluorescence staining, cultured cells rinsed 
three times with PBS and fixed with 3.7% formaldehyde 
were then permeabilized with 0.1% Triton X-100. After 
blocking in 1% BSA for 1 hour, cells were incubated with 
the primary antibody in a moist, 4ºC chamber overnight, 
washed and then incubated for 1 hour with Alexa Fluor 
488 (in the dark), or 594 donkey anti-rabbit IgG (H 
+ L) antibody (Invitrogen, Grand Island, NY) at room 
temperature . Washed cells (3X; PBS containing 0.02% 
Tween 20), stained by mounting onto a slide with aqueous 
mounting medium containing 0.5 mg/ml 40–6-diamidino-
2-phenylindole, were examined with a fluorescence 
microscope (Nikon E800) at 400 × magnification.
Flow cytometry analysis
Flow cytometry was performed as described 
previously [62]. Trypsinized cells washed twice with 
PBS were fixed. Cells stained with antibodies to CD44 
or an IgG isotype (Santa Cruz) and labeled with Alexa 
488-conjugated secondary antibody were subjected to flow 
cytometric analysis.
Chromatin immunoprecipitation (ChIP)
ChIP analyses were performed using the Imprint 
ChIP Kit (Sigma–Aldrich) as described previously [27]. 
Briefly, cells crosslinked with formaldehyde at room 
temperature, were lysed with L1buffer (50 mM Tris, 
2 mM EDTA, 0.1% IGEPAL, 10% glycerol, 1 mM 
dithiothreitol, 1 mM phenylmethylsulfonyl fluoride 
and protease inhibitor mixture, pH 8.0) on ice. After 
centrifugation, the nuclear pellet was re-suspended in 
ChIP lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris 
and protease inhibitor mixture, pH 8.0), and sonicated. 
Following an overnight incubation with antibody, a 50% 
slurry of protein A-agarose/salmon sperm DNA was added 
for 3 h. Bound DNA–protein complexes were eluted and 
crosslinks released after a series of washes. PCR analysis 
used the purified DNA resuspended in TE buffer (10 mM 
Tris-HCl and 1 mM EDTA, pH 8.0).
Migration and wound healing assay
Experiments were performed as described previously 
[27]. For the migration assay, cells (5 × 105) were seeded 
onto the upper chamber in 200 μL of serum-free medium; 
the lower compartment was filled with 0.6 mL of DMEM 
media supplemented with 10% of FBS. After a 24 h 
incubation, migrated cells on the lower surface of the 
filter were fixed and stained using propidium iodide; cells 
on the upper side were removed using a rubber scraper. 
Fluorescent images were obtained; reported data are counts 
of migrated cells with experiments performed in triplicate.
Tumorsphere culture
The experimental protocol for tumorsphere 
formation was described previously [62]. Single-cell 
suspensions were prepared at a density of 4,000 cells per 
milliliter and seeded into six-well plates (2.0 mL per plate) 
coated with 1.2% poly-Hema (Sigma-Aldrich). Suspension 
cultures continued for 1–2 weeks until tumorspheres 
formed. Tumorspheres with diameter > 50 μM were 
counted. Recorded data are colony number obtained from 
10 separate views using a microscope. Experiments were 
repeated three times with duplication in each experiment.
Soft-agar and tumorigenesis assays
Soft-agar assays were performed as described 
previously [63]. Cells were suspended in 0.2 mL of 
Matrigel (Collaborative Biomedical Products, Becton 
Dickinson Labware, Bedford, MA) diluted 1:1(vol/vol) 
with growth medium supplemented with 10% FBS. Cell 
suspensions were then placed on top of a previously 
cast semisolid layer of 0.2 mL of 1% low–melting 
agarose in growth medium in each well of a 24-well 
plate. Colonies formed over a 2 wk period at 37°C in a 
humidified CO2 incubator. Colonies in four microscopic 
fields were then counted using an inverted microscope 
at 40× magnification and photographed. Reported data 
are the means and standard error from two independent 
experiments performed, in triplicate.
Statistical analysis
Data analysis used SPSS (Statistic Package for 
Social Sciences) 13.0 for Windows (SPSS Inc., Chicago, 
IL, USA). Unpaired Student’s t-tests or U-Mann Whitney 
tests determined statistical significance between groups 
with p values < 0.05 considered significant.
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